Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem cell transplantation.
Epistemonikos ID: 4846e0b314c212834932ab15a4b71c8aa544a80b
First added on: May 08, 2024